Tumor lysis syndrome at the beginning of thalidomide therapy for multiple myeloma [3]

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2212-

  Cany, L ^a   Fitoussi, O ^a   Boiron, J M ^a   Marit, G ^a  

^a Polyclinique Francheville   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; FUROSEMIDE; MELPHALAN; THALIDOMIDE; URATE OXIDASE; VINCRISTINE;

DRUG ELIMINATION; DRUG MEGADOSE; HUMAN; HYPERURICEMIA; KIDNEY FAILURE; LETTER; LYMPHOPROLIFERATIVE DISEASE; METABOLIC ACIDOSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; THALIDOMIDE; TUMOR LYSIS SYNDROME;

EID: 0037089681     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Effective treatments of advanced multiple myeloma refractory to alkylating agents
2. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
3. Pahrmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects
4. Antitumor activity of thalidomide in refractory multiple myeloma
5. Treatment of Waldenstrom's macroglobulinemia with thalidomide